This is the authors' abstract. We don't add key points for this paper.
BACKGROUND: The lower extremity is a high-risk site for complications after dermatologic surgery, yet validated tools for preoperative risk stratification are lacking. The 11-item modified Frailty Index (mFI-11) predicts surgical morbidity across numerous specialties but has not been studied in dermatologic surgery. OBJECTIVE: To determine whether the mFI-11 predicts adverse outcomes after surgery for lower-extremity nonmelanoma skin cancer (NMSC). METHODS: Retrospective review of 103 cases of biopsy-proven invasive lower-extremity NMSC treated with excision or Mohs micrographic surgery at a single academic center between 2023 and 2026. Outcomes were analyzed with cluster-robust logistic and Poisson regression. RESULTS: Adverse events occurred in 38% of cases, increasing monotonically across frailty categories (23% to 67%). Frail patients (≥3 mFI-11 items) had greater odds of any adverse event (67% vs 29%; OR 4.87; 95% CI 1.81-13.07), more complications per case (rate ratio 1.32 per item), longer wound-care episodes (median 48 vs 21 days), and more frequent wound-care escalation (54% vs 15%). Frailty remained independently predictive after adjustment for defect size, age, and sex (adjusted OR 1.69 per item; 95% CI 1.17-2.43). CONCLUSION: The mFI-11 is a low-cost, graded, independent predictor of adverse outcomes after lower-extremity NMSC surgery and may aid preoperative risk stratification and counseling.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Learned et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: